Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Resistance to osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is a significant challenge for patients with advanced EGFR-mutant lung adenocarcinoma (LUAD). Fat mass and obesity-associated protein (FTO), an N-methyladenosine (mA) demethylase, plays a critical role in the occurrence, metastasis, and drug resistance of various tumors. We found that high FTO expression was significantly associated with resistance to osimertinib in advanced LUAD patients harboring EGFR mutations. In vitro experiments indicated that FTO enhanced the resistance of LUAD cells to osimertinib by reducing mA modification. FTO silencing induced G0/G1 phase arrest in resistant cells in an mA-dependent manner, restoring osimertinib sensitivity. Both in vivo and in vitro studies showed that FB23-2, an FTO inhibitor, synergistically suppressed the growth of resistant cells in combination with osimertinib. Furthermore, LUAD patient-derived organoids maintained histological and genetic consistency with patient tissues, where FTO was highly expressed in osimertinib-resistant organoids. The combination of FB23-2 and osimertinib effectively inhibited the growth of osimertinib-resistant organoids. Overall, this study demonstrates that FTO promotes osimertinib resistance and targeting FTO induces G0/G1 arrest in an mA-dependent manner. The combination of FTO inhibitor and osimertinib provides a strategy to override osimertinib resistance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bcp.2025.117198 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identifying meaningful drug response biomarkers from public pharmacogenomic datasets with biologically informed interpretable neural networks.
Comput Biol Chem
September 2025
Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa, Macao Special Administrative Region of China. Electronic address:
With the advancements of next-generation sequencing, publicly available pharmacogenomic datasets from cancer cell lines provide a handle for developing predictive models of drug responses and identifying associated biomarkers. However, many currently available predictive models are often just used as black boxes, lacking meaningful biological interpretations. In this study, we made use of open-source drug response data from cancer cell lines, in conjunction with KEGG pathway information, to develop sparse neural networks, K-net, enabling the prediction of drug response in EGFR signaling pathways and the identification of key biomarkers.
View Article and Find Full Text PDFImpact of rare EGFR exon 19 insertion-deletion variants on tyrosine kinase inhibitor efficacy in non-small-cell lung cancer: a 5-year multicenter analysis.
ESMO Open
September 2025
Department of Pulmonary and Critical Care Medicine, Fuzong Clinical Medical College of Fujian Medical University & The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, China. Electronic address:
Background: The clinical impact of rare epidermal growth factor receptor (EGFR) exon 19 insertion-deletion (19delins) variants on tyrosine kinase inhibitor (TKI) efficacy remains poorly characterized. We updated 5-year outcomes to evaluate long-term survival and optimal treatment strategies in advanced lung adenocarcinoma (LUAD) patients harboring these mutations.
Materials And Methods: In this multicenter prospective study, 36 treatment-naive advanced LUAD patients with EGFR 19delins mutations received first-generation (n = 26) or third-generation TKIs (n = 10).
A Hybrid Protein-Oxygen Nanomedicine Overcomes Osimertinib Resistance in NSCLC via HIF-1α/VEGF/EGFR Inhibition.
Int J Nanomedicine
September 2025
Department of Thoracic Surgery, Tenth Affiliated Hospital, Southern Medical University (Dongguan People's hospital), Dongguan, Guangdong, 523059, People's Republic of China.
Purpose: Osimertinib, established as the frontline treatment for advanced non-small cell lung cancer (NSCLC), can effectively prolong progression-free survival. However, it faces the problem of reduced treatment persistence due to acquired drug resistance. Meanwhile, tumor hypoxia is also a key driver of drug resistance.
View Article and Find Full Text PDFTargeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer.
Cancer Lett
August 2025
Departments of Hematology and Medical Oncology and Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, GA, USA. Electronic address:
c-Myc inhibition is a critical mechanism in mediating the therapeutic efficacy of osimertinib against EGFR mutant (EGFRm) NSCLCs and accordingly targeting c-Myc is an effective strategy for overcoming osimertinib acquired resistance, a challenging issue in the clinic. However, lack of specific c-Myc inhibitors restricts the application of this strategy. The current study focused on determining the potential application of an alternative c-Myc inhibitory approach to overcome osimertinib acquired resistance via targeting the MKK3/c-Myc interaction that stabilizes c-Myc protein.
View Article and Find Full Text PDFStrategies of overcoming osimertinib resistance in EGFR-mutated non-small cell lung cancer.
J Drug Target
September 2025
Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China.
Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has significantly advanced the treatment of non-small cell lung cancer (NSCLC), particularly in patients who develop resistance to first- and second-generation EGFR-TKIs. However, most patients inevitably develop resistance to the treatment, which presents a major challenge for long-term disease control. The molecular mechanisms underlying osimertinib resistance are complex and are generally categorised into EGFR-dependent and EGFR-independent pathways.
View Article and Find Full Text PDF